• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[卵巢癌治疗标准]

[Therapeutic standards for ovarian cancer].

作者信息

Pfisterer J, du Bois A

机构信息

Klinik für Gynäkologie und Geburtshilfe Campus Kiel, Universitätsklinikum Schleswig-Holstein, Michaelisstrasse 16, 24105 Kiel, Germany.

出版信息

Pathologe. 2007 May;28(3):222-8. doi: 10.1007/s00292-007-0907-9.

DOI:10.1007/s00292-007-0907-9
PMID:17396269
Abstract

Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate. Recently, numerous findings have emerged on the status and extent of surgical therapy for this disease. Innovations in the chemotherapy of primary and recurrent disease are also plentiful. It is essential for the improvement of the patients' situation to transfer these new developments, already integrated into national and international standards and guidelines, into clinical practice.

摘要

上皮性卵巢癌是死亡率最高的妇科肿瘤。最近,关于这种疾病手术治疗的现状和范围出现了许多研究结果。原发性和复发性疾病化疗方面的创新也很多。将这些已纳入国家和国际标准及指南的新进展应用于临床实践,对于改善患者状况至关重要。

相似文献

1
[Therapeutic standards for ovarian cancer].[卵巢癌治疗标准]
Pathologe. 2007 May;28(3):222-8. doi: 10.1007/s00292-007-0907-9.
2
[First-line therapy in ovarian cancer].[卵巢癌的一线治疗]
Zentralbl Gynakol. 2004 Oct;126(5):312-4. doi: 10.1055/s-2004-820390.
3
[Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].[卵巢癌腹膜转移。方法及治疗结果]
Chirurg. 2007 Dec;78(12):1111-6. doi: 10.1007/s00104-007-1431-4.
4
[Adjuvant chemotherapy in primary radically operated ovarian cancer].
Onkologie. 1985 Oct;8(5):316, 321-3.
5
[Chemotherapy and prognostic significance of the size of the remaining tumor in ovarian cancer].[卵巢癌化疗及残余肿瘤大小的预后意义]
Gynakol Rundsch. 1989;29 Suppl 2:413-4.
6
[Initial treatment for ovarian cancer].[卵巢癌的初始治疗]
Gan To Kagaku Ryoho. 2009 Feb;36(2):224-9.
7
Current aspects of adjuvant therapy of early stage ovarian cancer.早期卵巢癌辅助治疗的当前进展
Zentralbl Gynakol. 1998;120(3):93-7.
8
[Ovarian cancer from the standpoint of medical oncology].[从医学肿瘤学角度看卵巢癌]
Gan To Kagaku Ryoho. 2007 Jul;34(7):1017-21.
9
[Current status of the management of patients with malignant ovarian cancer in Hungary].[匈牙利恶性卵巢癌患者的管理现状]
Orv Hetil. 1997 Feb 16;138(7):405-11.
10
Chemotherapy and radiation therapy in the treatment of ovarian carcinoma of common epithelial origin.化疗和放射疗法在常见上皮来源卵巢癌治疗中的应用
Clin Obstet Gynecol. 1985 Dec;28(4):806-15. doi: 10.1097/00003081-198528040-00015.

引用本文的文献

1
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.碳酸酐酶 IX(CAIX)的过表达是子宫内膜样卵巢癌的一个独立的不良预后标志物。
Virchows Arch. 2011 Aug;459(2):193-200. doi: 10.1007/s00428-011-1105-y. Epub 2011 Jun 21.

本文引用的文献

1
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).2004年卵巢癌管理共识声明:第三届国际妇科癌症 Intergroup 卵巢癌共识会议(GCIG OCCC 2004)最终文件
Ann Oncol. 2005;16 Suppl 8:viii7-viii12. doi: 10.1093/annonc/mdi961.
2
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.系统主动脉和盆腔淋巴结清扫术与仅切除减瘤至最佳状态的晚期卵巢癌肿大淋巴结的比较:一项随机临床试验。
J Natl Cancer Inst. 2005 Apr 20;97(8):560-6. doi: 10.1093/jnci/dji102.
3
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
顺铂/紫杉醇与卡铂/紫杉醇作为卵巢癌一线治疗的随机临床试验。
J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9. doi: 10.1093/jnci/djg036.
4
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.卡铂与紫杉醇联合方案对比顺铂与紫杉醇联合方案用于 III 期卵巢癌最佳减瘤术后患者的 III 期临床试验:一项妇科肿瘤学组研究
J Clin Oncol. 2003 Sep 1;21(17):3194-200. doi: 10.1200/JCO.2003.02.153. Epub 2003 Jul 14.
5
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.紫杉醇联合铂类化疗与传统铂类化疗用于复发性卵巢癌女性的疗效比较:ICON4/AGO-OVAR-2.2试验
Lancet. 2003 Jun 21;361(9375):2099-106. doi: 10.1016/s0140-6736(03)13718-x.
6
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.国际卵巢癌协作组试验1:早期卵巢癌女性辅助化疗的随机试验。
J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. doi: 10.1093/jnci/95.2.125.
7
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.辅助化疗和手术分期对早期卵巢癌的影响:欧洲癌症研究与治疗组织-卵巢肿瘤辅助化疗试验
J Natl Cancer Inst. 2003 Jan 15;95(2):113-25.
8
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.紫杉醇联合卡铂与单药卡铂或环磷酰胺、阿霉素和顺铂的标准化疗方案用于卵巢癌女性患者的疗效比较:ICON3随机试验
Lancet. 2002 Aug 17;360(9332):505-15. doi: 10.1016/S0140-6736(02)09738-6.
9
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.铂类时代最大程度肿瘤细胞减灭术对晚期卵巢癌的生存影响:一项荟萃分析。
J Clin Oncol. 2002 Mar 1;20(5):1248-59. doi: 10.1200/JCO.2002.20.5.1248.
10
Staging of early ovarian cancer and the impact of lymph node sampling.早期卵巢癌的分期及淋巴结取样的影响
Int J Gynecol Cancer. 2000 Jan;10(S1):8-11. doi: 10.1046/j.1525-1438.2000.99503.x.